News from the department of Internal medicine
Latest entry in the department of Internal medicine:
Mavamcampten
Mavamcampten Definition Selective, cardiac myosin inhibitor. Mavacampten is the first and so far only drug approved in this drug class. (Approved in Europe since 2023, approved in the USA since 2022). Classification Pharmacodynamics (Effect) Mechanism of action: Mavacampten is an allosteric, sele...
Go to articleRecent search terms:
69,009
173,939
16,759
Prof. Dr. med. Peter Altmeyer
Editor-in-Chief
One of Germany's most accomplished dermatologists with decades of expertise in clinical dermatology. Emeritus professor at the Ruhr-Universität Bochum, author of more than 30 textbooks and over 700 scientific publications.